➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
McKesson
McKinsey
Johnson and Johnson
Baxter

Last Updated: October 20, 2021

DrugPatentWatch Database Preview

SOAANZ Drug Patent Profile


Email this page to a colleague

« Back to Dashboard

When do Soaanz patents expire, and when can generic versions of Soaanz launch?

Soaanz is a drug marketed by Sarfe Pharms and is included in one NDA. There is one patent protecting this drug.

This drug has two patent family members in two countries.

The generic ingredient in SOAANZ is torsemide. There are sixteen drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the torsemide profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Soaanz

A generic version of SOAANZ was approved as torsemide by TEVA on May 14th, 2002.

  Free Forever Trial

Summary for SOAANZ
International Patents:2
US Patents:1
Applicants:1
NDAs:1
Formulation / Manufacturing:see details
DailyMed Link:SOAANZ at DailyMed
Drug patent expirations by year for SOAANZ

US Patents and Regulatory Information for SOAANZ

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sarfe Pharms SOAANZ torsemide TABLET;ORAL 213218-001 Jun 14, 2021 RX Yes Yes ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
Sarfe Pharms SOAANZ torsemide TABLET;ORAL 213218-002 Jun 14, 2021 RX Yes No ⤷  Free Forever Trial ⤷  Free Forever Trial Y ⤷  Free Forever Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Moodys
McKesson
McKinsey
Johnson and Johnson
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.